dutasteride tablet (AD-208) / Yuhan Corp - LARVOL DELTA

Review of Medical Therapy Options in Updated AUA Guidelines for BPH Management, Journal Club - Rashid Sayyid & Zachary Klaassen (Urotoday) - "...and Zach Klaassen discuss the AUA's updated guidelines for managing lower urinary tract symptoms due to BPH, with a focus on medical therapy. They recommend alpha blockers for moderate to severe symptoms, noting all types have similar efficacy in improving IPSS scores. The choice of alpha blocker should be based on patient age, comorbidities, and side effects like ejaculatory dysfunction or blood pressure changes. For prostatic enlargement, 5-alpha reductase inhibitors (5-ARIs) are advised, effectively reducing prostate size and symptoms, with both finasteride and dutasteride being equally effective."

Video

A Study to Evaluate the Efficacy and Safety of AD-208 (clinicaltrials.gov) - P3 | N=139 | Completed | Sponsor: Addpharma Inc. | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Sep 2022 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Alopecia

A Study to Evaluate the Efficacy and Safety of AD-208 (clinicaltrials.gov) - P3; N=130; Recruiting; Sponsor: Addpharma Inc.; Trial completion date: Apr 2022 ➔ Dec 2022; Trial primary completion date: Oct 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Alopecia

A Study to Evaluate the Efficacy and Safety of AD-208 (clinicaltrials.gov) - P3; N=130; Recruiting; Sponsor: Addpharma Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alopecia

A Study to Evaluate the Efficacy and Safety of AD-208 (clinicaltrials.gov) - P3; N=130; Not yet recruiting; Sponsor: Addpharma Inc.

New P3 trial • Alopecia

To Evaluate the Pharmacokinetics and Safety of AD-208 (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Addpharma Inc.; Recruiting ➔ Completed

Clinical • Trial completion • Alopecia

To Evaluate the Pharmacokinetics and Safety of AD-208 (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Addpharma Inc.

Clinical • New P1 trial